Zacks Research Brokers Boost Earnings Estimates for Avantor

Avantor, Inc. (NYSE:AVTR) – Stock analysts at Zacks Research increased their Q2 2026 EPS estimates for Avantor in a research report issued on Tuesday, December 10th. Zacks Research analyst D. Dey now anticipates that the company will post earnings of $0.29 per share for the quarter, up from their prior estimate of $0.28. The consensus estimate for Avantor’s current full-year earnings is $0.98 per share.

Several other research analysts have also recently issued reports on the stock. UBS Group lowered their target price on shares of Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, October 8th. Robert W. Baird decreased their target price on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Wells Fargo & Company reduced their price objective on Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Royal Bank of Canada reiterated an “outperform” rating and set a $34.00 price target on shares of Avantor in a research note on Thursday, September 26th. Finally, Barclays decreased their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $27.69.

Avantor Trading Down 0.9 %

NYSE:AVTR opened at $22.33 on Friday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. Avantor has a 1 year low of $19.59 and a 1 year high of $28.00. The stock has a market cap of $15.20 billion, a P/E ratio of 48.54, a P/E/G ratio of 2.75 and a beta of 1.29. The stock has a 50-day simple moving average of $22.47 and a 200-day simple moving average of $23.53.

Institutional Trading of Avantor

Large investors have recently modified their holdings of the business. Hantz Financial Services Inc. boosted its position in Avantor by 2.1% during the third quarter. Hantz Financial Services Inc. now owns 24,900 shares of the company’s stock worth $644,000 after acquiring an additional 503 shares during the last quarter. Intech Investment Management LLC raised its holdings in Avantor by 1.8% in the second quarter. Intech Investment Management LLC now owns 29,068 shares of the company’s stock valued at $616,000 after buying an additional 514 shares during the period. Arizona State Retirement System raised its stake in shares of Avantor by 0.3% during the second quarter. Arizona State Retirement System now owns 186,567 shares of the company’s stock valued at $3,955,000 after purchasing an additional 528 shares during the period. Veracity Capital LLC lifted its position in shares of Avantor by 1.0% during the third quarter. Veracity Capital LLC now owns 52,359 shares of the company’s stock worth $1,355,000 after purchasing an additional 543 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Avantor by 2.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 26,921 shares of the company’s stock valued at $571,000 after purchasing an additional 733 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.